India Needs Innovative Strategies to Eliminate Tuberculosis (TB)

After Reading This Article You Can Solve This UPSC Mains Model Question:   

“Tuberculosis in India is as much a social and nutritional disease as it is a medical challenge.” Critically examine the key bottlenecks in eliminating TB in India, and suggest an innovative, community-centered roadmap for the future. 15 Marks (GS-2, Health)
Context

• More than a century after the introduction of the Bacillus Calmette–Guérin (BCG) vaccine, tuberculosis (TB) remains one of the world’s deadliest infectious diseases, disproportionately affecting low- and middle-income countries (LMICs) such as India.
• Recently, findings from the PreVenTB trial have highlighted the potential of targeted vaccination strategies, reinforcing the need for a comprehensive approach that combines vaccination, early detection, preventive therapy, and nutritional support to achieve TB elimination.

Tuberculosis Continuing to be a Major Public Health Challenge in India

A. Complex Nature of TB Infection

• TB infection does not follow a single pathway, making disease control difficult.
• After exposure to Mycobacterium tuberculosis, some individuals remain asymptomatic, some develop latent infection, while others progress to active disease.
• Active TB can appear as:
  • Pulmonary TB (PTB) affecting the lungs and driving transmission.
  • Extrapulmonary TB (EPTB) affecting organs such as lymph nodes, bones, brain, kidneys, and intestines.

B. Burden of Disease Remains High

• Highest burden in the world: India accounts for roughly 25% of global TB cases and the highest number of drug-resistant TB cases (about 32% of the global total), making it the epicentre of the disease.
• Real but insufficient progress: India’s TB incidence has fallen by about 21% (from 237 to 187 cases per lakh) in roughly the last decade, nearly double the global pace, while TB deaths have dropped from 28 to 21 per lakh, but this is still far short of the elimination goal.
• A systemic problem: In many low- and middle-income countries, TB incidence runs at 200–300 per 100,000, and bringing it down to the elimination threshold of 10–20 per 100,000 demands sustained effort and large-scale public health investment.

C. Challenges Associated with Extrapulmonary TB

• EPTB is often difficult to diagnose due to non-specific symptoms.
• It frequently remains undetected for long periods, resulting in severe complications and higher healthcare costs.
• Delayed diagnosis often leads to disability and poor treatment outcomes.

D. Why a “One-Shot” Vaccine Is Unrealistic

• As TB follows so many different pathways in the body, expecting a single vaccine to prevent every form of the disease is impractical and has fuelled repeated global disappointment.
• Most earlier vaccine trials targeted only pulmonary TB, leaving the dangerous extrapulmonary form largely untested and unaddressed.

The PreVenTB Trial: A Landmark Development in TB Vaccination

1. About the Trial

• The PreVenTB trial, conducted by ICMR across 18 sites in India and involving over 12,700 household contacts of TB patients, is the world’s first Phase III TB vaccine trial to evaluate protection against both Pulmonary TB (PTB) and Extrapulmonary TB (EPTB) under real-world conditions.
• Two Candidates: It evaluated VPM1002 (a single-dose, modified BCG-based vaccine) and Immuvac, including people with other illnesses and varying infection status, closely reflecting real life.

2. Key Findings: VPM1002

• VPM1002, developed by the Serum Institute of India (SIIPL), is a modified recombinant BCG vaccine designed to generate a stronger immune response.
• It demonstrated 21.4% efficacy against all forms of TB (PTB and EPTB combined) across the study population.
• Notably, it showed 50.4% efficacy against Extrapulmonary TB, marking the first significant evidence of vaccine protection against EPTB.
• Among children aged 6–14 years, efficacy reached 64.6% against all forms of TB, highlighting the potential for a school-age booster vaccination strategy.
• As a single-dose vaccine, VPM1002 offers important operational advantages for large-scale deployment.

3. Key Findings: Immuvac

• Immuvac, developed by Cadila Pharmaceuticals, demonstrated over 60% efficacy against EPTB among children aged 6–10 years.
• It also showed more than 60% efficacy in preventing progression from latent TB infection to active disease, indicating its potential role in interrupting disease development and transmission.

4. Why This Trial Matters?

• Tackling the hidden epidemic: A reduction of over 50% in extrapulmonary cases delivers a real clinical and public health impact, lowering both healthcare costs and patient suffering.
• Protecting school-age children: The strong signal of over 60% efficacy in children and adolescents is vital because India currently has no structured TB vaccination strategy beyond infancy, opening the door to a possible booster-dose approach.
• Nutrition Link: Vaccine protection was weaker in people with low Body Mass Index (BMI), proving that nutritional support is essential for vaccines to work well in undernourished populations.

Key Challenges in TB Elimination

• Uneven Access to Diagnostics and Prevention: Access to tools for detecting latent and subclinical TB remains patchy in rural, tribal, and urban slum areas, allowing silent infection reservoirs to persist. Access to preventive therapy is equally uneven, making targeted vaccination a critical pillar rather than an optional add-on.
• Drug Resistance: The growing burden of Multidrug-Resistant TB (MDR-TB) and Extensively Drug-Resistant TB (XDR-TB), worsened by incomplete treatment and antibiotic misuse, demands longer, costlier, and more toxic regimens, straining the health system and pushing patients toward treatment abandonment.
• Social Vulnerabilities and Poverty: TB thrives on undernutrition, overcrowded housing, poor ventilation, HIV, diabetes, and tobacco use. Stigma, especially among women, further delays care and fuels household transmission, making medical interventions alone insufficient.
• Funding fragility: Global TB financing has stagnated, threatening hard-won gains, while India must reduce dependence on unpredictable international donor funding.
• Perfect Vaccine Trap: Waiting for a single ideal vaccine has cost decades of progress, when moderately effective vaccines deployed strategically can deliver immediate public health gains, as India’s rotavirus and COVID-19 experience clearly demonstrated.

India’s Existing TB Elimination Architecture

• National TB Elimination Programme (NTEP): The National TB Elimination Programme (NTEP), implemented under the National Health Mission (NHM), follows the Detect–Treat–Prevent–Build (DTPB) strategy and aims to achieve TB elimination by 2025, five years ahead of the global United Nations SDG 2030 target.
• Pradhan Mantri TB Mukt Bharat Abhiyaan: The Pradhan Mantri TB Mukt Bharat Abhiyaan seeks to transform TB elimination into a Jan Andolan (People’s Movement) through the Ni-kshay Mitra Initiative, which enables individuals, NGOs, institutions, and corporate entities to support TB patients with nutritional, social, and community assistance.
• Ni-kshay Poshan Yojana: Strengthening Nutritional Support: Under the Ni-kshay Poshan Yojana, monthly nutritional assistance has recently been increased from ₹500 to ₹1,000 through Direct Benefit Transfer (DBT), complemented by Energy Dense Nutrition Supplementation (EDNS) for undernourished TB patients.
• Promoting Indigenous Public Health Innovation: India has demonstrated a willingness to adopt home-grown health innovations, including the early deployment of the TrueNat molecular diagnostic test, the emergency approval of Covaxin during the COVID-19 pandemic, and the introduction of the indigenous Rotavirus vaccine despite modest initial efficacy, reflecting a pragmatic and innovation-driven public health approach.

Way Forward for a Smarter TB Elimination Strategy

• Strengthen Early Detection: Wider deployment of TrueNat, CBNAAT (GeneXpert), and AI-powered screening tools must reach every primary health centre to catch latent and subclinical TB before it progresses and spreads.
• Scale Up Preventive Therapy: Latent TB Preventive Therapy (LTPT) must be systematically provided to household contacts, healthcare workers, diabetics, HIV patients, and immunocompromised individuals as a non-negotiable second layer of prevention.
• Deploy Targeted Vaccination: VPM1002 and Immuvac must be rolled out first among household contacts and school-age children aged 6 to 14 years, where trial efficacy was highest, using a combination multi-vaccine framework since no single vaccine covers all TB forms.
• Integrate Nutrition: Nikshay Poshan Yojana must be expanded and nutritional support treated as a medical intervention, not merely welfare, since low BMI directly reduces vaccine effectiveness and disease resistance.
• Address Drug Resistance: Stronger surveillance and strict treatment adherence protocols are essential to contain Multidrug-Resistant TB (MDR-TB) and Extensively Drug-Resistant TB (XDR-TB).
• Build Community-Centred Systems: Reducing stigma, strengthening frontline health workers, and building on India’s own precedents of Covaxin and rotavirus vaccines will ensure that urgency drives policy over the pursuit of perfection.

Conclusion

India’s TB challenge will not be solved by one miracle vaccine but by the smart, combined use of early detection, prevention, targeted vaccination, and nutrition support. By deploying the tools available today, especially those that reduce the dangerous extrapulmonary form of the disease, India can convert its ambitious elimination goal into a realistic and achievable public health success.